Zhejiang East Asia Pharmaceutical Co., Ltd.

Sales of Atopic Dermatitis to Grow Ten-Fold as Key Companies Line up for Fast-Track Approval & Product Development In its latest report, Fact.MR presents an elaborate analysis of various factors influencing the global atopic dermatitis market, including drivers, opportunities, restraints, and trends. It further delves deeper into major observations concerning prominent expansion parameters prevailing across key segments, including drug class, distribution channel, and regions. NEW YORK, Nov. 28, 2022 /PRNewswire/ -- The global atopic dermatitis market is poised to expand at 24% CAGR between 2022 and 2032, surpassing a valuation of US$ 7.3 Billion by the end of 2022. Growth in the market is primarily attributed to the rising prevalence of eczema and other skin disorders across the globe. With increasing awareness regarding the skin diseases, the need for early detection is another factor driving the demand in the market. Atopic dermatitis is considered to be a chronic skin disorder which results in cracked and inflammation of the skin. With loss of skin barrier, the patient becomes more prone to infection and any other disorders. As per the research, around 15 million Americans were affected by atopic dermatitis in 2017. In 2020, as per the Acta Derm Venereologica Journal, prevalence of doctor diagnosed atopic dermatitis in Europe was 17.1% and 22.6% of children in Asia. This is encouraging the government bodies and health professionals to develop a cure and treatment rapidly. Consequently, leading companies are extensively investing in research to develop proper drug and biologics to reduce the global burden. Download A Free Sample of this Report! Further, with rising awareness regarding the skin disease along with improved healthcare infrastructure in developed economies such as U.S., Japan, U.K., and Germany, the demand in the market is predicted to rise. As per Fact.MR, the leading companies are introducing innovative procedure and formulations to gain competitive edge. For instance, in 2021, the U.S. Food and Drug Administration (FDA) approved Pfizer's Cibinqo and AbbVie's Rinvoq to treat moderate to severe atopic dermatitis for the patients who were unresponsive to the other treatments. Likewise, in January 2022, Eli Lilly and Company and Incyte announced the development of their Phase 3 program for OLUMIANT® in adults with active systemic lupus erythematosus and the status of the U.S. atopic dermatitis supplemental new drug application. Key Takeaways: Based on drug class, the biologics drugs segment is poised to expand at a whopping 32.4% CAGR during the forecast period. In terms of distribution channel, the retail pharmacies segment is slated to grow at a CAGR of 27.4% over the upcoming decade. Europe is expected to dominate the global atopic dermatitis market, registering growth at 25.5% CAGR for the forecast period. Increasing prevalence of atopic dermatitis coupled with rising approval of drugs & treatments in the U.S. will push the growth in North America. China is expected to witness impressive growth in the East Asia atopic dermatitis market on the back of rising number of CROs and other research organizations. Increased spending on healthcare and favorable policies in India will push the demand for atopic dermatitis in South Asia market. Growth Drivers: Fast track drug approvals and extensive research & development for the product development is expected to drive the demand in the market. Availability of treatment and drugs across online pharmacies will spur the demand in the market. Growing awareness regarding the disease coupled with favorable policies and initiatives by non-profit organizations is anticipated to boost the market. Restraints: Side effects of the biologics and the treatment for atopic dermatitis might hamper the growth in the market. High treatment cost in developing countries coupled with lack of reimbursement policies is likely to limit the sales. Don't Need a Global Report? Save 40% on Country & Region Specific Reports Competitive Landscape: As per Fact.MR, the market is expected to be dominated by Pfizer Inc., LEO Pharma A/S, Teva Pharmaceutical, Novartis AG, Sanofi, and Mylan M.V. These six key companies are continuously focusing on research and development of novel drug development to maintain their position in the industry. They are also focusing on product development and fast drug approvals from regulatory authorities such as the U.S. Food and Drug Administration (FDA) to gain competitive edge. Meanwhile, other players are forming alliances with leading companies to expand their product portfolio and capitalize on the established brand of the leading company. For instance, In October 2022, leading player LEO Pharma unveiled that Adtralza, a biologic that neutralizes and targets the interleukin for adolescents with moderate-to-severe atopic dermatitis, was approved by European Commission Approval for marketing. Almirall, S.A., a global biopharmaceutical company, focused on skin health, in October 2022, announced that the European Medicines Agency accepted the filling of the marketing authorization application for lebrikizumab for the treatment of moderate to severe dermatitis. Key Companies Profiled by Fact.MR Mylan M.V. Pfizer Inc. LEO Pharma A/S Teva Pharmaceutical Industries Ltd Sanofi Novartis AG. More Valuable Insights on Atopic Dermatitis Market In the latest study, Fact.MR reveals key factors expected to boost the growth in global atopic dermatitis market during the forecast period (2022-2032). The survey also provides an in-depth analysis of opportunities and drivers projected to propel sales of atopic dermatitis through detailed segmentation as follows: Drug Class: Corticosteroids PDE4 Inhibitors Biologics Skin Barrier Emollients CNI Immunosuppressants Others Distribution Channel: Hospital Pharmacies Retail Pharmacies Online Pharmacies Regions: North America Latin America Europe East Asia South Asia Oceania MEA Get Full Access of this Report through our Secure Payment Gateway Key Questions Covered in the Atopic Dermatitis Market Report What will be the demand outlook for the atopic dermatitis market during the forecast period? Which are the challenges faced in the atopic dermatitis market? Which region will lead the growth in the global atopic dermatitis market during 2022-2032? What is the projected market valuation of the atopic dermatitis market in 2032? Which are the factors driving the atopic dermatitis during 2022-2032? Which drug class will generate maximum revenue in the global atopic dermatitis market? Explore Fact.MR's Coverage on the Healthcare Domain Skin Antiseptic Market: With increasing prevalence of chronic skin disorders, the demand for skin antiseptic is expected to surge at a rapid pace. Due to the rising number of infection and contamination with pathogenic organisms, the need for proper treatment has increased the demand for skin antiseptics over the upcoming decade. As per the study, Europe is expected to dominate the market, with the U.K. leading the growth. Inflammatory Skin Diseases Treatment Market: The market for inflammatory skin diseases treatment is expected to grow at a robust pace over the forecast period. This type of skin disease treatment is associated with diabetes and psoriasis arthritis. Growing prevalence of genetic skin disorders across the globe is expected to drive the demand in the market. Fact.MR estimates, North America will account for significant share in the market. Frozen Skin Graft Market: Rising incidence of burn-related injuries and extensive wounds is propelling the growth in the frozen skin graft market. With growing prevalence of diabetic ulcers and preference for minimally invasive procedures will drive the demand in the market. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D) E: [email protected] Follow Us: LinkedIn | Twitter | YouTube Logo: SOURCE Fact.MR

Cancer Biomarkers & Pharmaceutical Companies Lining Up for Clinical Trials to Cater to Growing Demand, Pushing Sales Past US$ 11 Billion in 2022 In its latest report, Fact.MR presents an elaborate analysis of various factors influencing the global cancer biomarkers market, including drivers, opportunities, restraints, and trends. It further delves deeper into major observations concerning prominent expansion parameters prevailing across key segments, including test type, illness indication, and regions. ROCKVILLE, Md., Nov. 23, 2022 /PRNewswire/ -- The global cancer biomarkers market reached a total of US$ 9.1 Billion in 2021 and is expected to exceed US$ 11 Billion by the end of 2022. Growing prevalence of cancer and adoption of cancer medicines is aiding the growth in the market. As per the study, the demand in the market is expected to increase at 12% CAGR over the forecast period of 2022 and 2032. As awareness regarding regular health check-up is increasing, the demand for early diagnosis is expected to propel the use of cancer biomarkers. Hence, key companies are investing in research activities to develop novel diagnostic products and gain competitive edge. Several pharmaceutical companies are also investing in development of novel biomarkers for cancer treatment and diagnosis. As per the National Library of Medicine, around 1,515 cancer biomarkers are currently in clinical trials. In addition to this, as prevalence of lung cancer is increasing, the governments across the globe are increasing their initiatives to curb the global burden. The growing footfall of patients related to this disease is creating the need for cancer biomarkers. As per the Lung Cancer Facts 2022, around 236,740 people are expected to be diagnosed with lung cancer in 2022. As passive smoking, air pollution, and toxic environment due to industrial mills and factories continues to surge, the global burden of lung cancer is predicted to increase, resulting in growing need for biomarkers. Download A Free Sample Report! Apart from lung cancer, breast cancer is expected to be the leading cause resulting in the dire need for cancer biomarkers. With growing awareness regarding the early detection of breast cancer and cyst in breast, the governments worldwide are investing extensively in developing the biomarkers to detect the disease at an early stage. As per the study, breast cancer held the largest share in 2021 and is expected to remain dominant over other illness indication during the upcoming decade. However, due to the growing incidence of prostate cancer, especially among men, the demand for PSA testing is expected to increase over the next decade. Fact.MR opines, Europe is expected to account for significant portion for prostate-specific antigen (PSA) testing, contributing nearly 50% of sales. Key Takeaways: North America is expected to account for nearly 2/5th of revenue, creating an absolute US$ 5.2 Billion market opportunity in 2032. Asia Pacific is projected to register 12% CAGR during the forecast period, with China and Japan leading the growth in the region. Europe cancer biomarkers market is expected to exhibit growth at 11.6% CAGR over the upcoming decade. Over half the revenue in the global market is expected to come from the PSA testing technology, in terms of test type. Based on indication, breast cancer is expected to account for highest share, followed by prostate cancer. Growth Drivers: Growing need for cancer biomarkers for drug discovery and development will propel the growth in the market. Rising awareness towards the personalized medicine and need for early detection to curb the global burden will fuel the demand in the market. Favorable government funding and initiatives to reduce the mortality rates due to cancer will aid the growth in cancer biomarkers market. Restraints: High cost of investments and extensive timeline issues in development and sample recovery might limit the growth. Unfavorable regulatory scenarios in low income countries and unavailability of skilled professionals & diagnostic centers might hamper the demand. Get Customization on this Report (Save 40% on Country & Region Specific Reports) Competitive Landscape: Fact.MR estimates, the market for cancer biomarkers to be fiercely competitive. F. Hoffmann-La Roche is considered to be the leading company dominating the market, followed by two other leading players, namely Thermo Fisher Scientific and Qiagen N.V. Key players in the market are investing extensively in research and development activities to develop novel products and stay ahead in the competition. For instance, In September 2022, Bertis announced the launch of proteomic based research results of new biomarker for ovarian cancer diagnosis. Oxford cancer biomarkers, in September 2022, announced the availability of ToxNav, pharmacogenomics test for predicting genetic susceptibility to toxicity from chemotherapy to clinicians in Europe. Key Companies Profiled by Fact.MR F. Hoffmann-La Roche Ltd TECENTRIQ Abbott Laboratories Thermo Fisher Scientific Inc. Agilent Technologies Illumina Inc. bioMerieux SA Hologic Inc. Genomic Health Inc. QIAGEN More Valuable Insights on Cancer Biomarkers Market In the latest study, Fact.MR reveals key factors expected to boost the growth in global cancer biomarkers market during the forecast period (2022-2032). The survey also provides an in-depth analysis of opportunities and drivers projected to propel sales of cancer biomarkers through detailed segmentation as follows: Test Type: PSA Cancer Biomarker Tests CTC Cancer Biomarker Tests AFP Cancer Biomarker Tests CA Cancer Biomarker Tests HER2 Cancer Biomarker Tests BRCA Cancer Biomarker Tests ALK Cancer Biomarker Tests CEA Cancer Biomarker Tests EFGR Mutation Cancer Biomarker Tests KRAS Mutation Cancer Biomarker Tests Other Cancer Biomarker Tests Illness Indication: Blood Cancer Biomarkers Prostate Cancer Biomarkers Ovarian Cancer Biomarkers Stomach Cancer Biomarkers Liver Cancer Biomarkers Other Cancer Biomarkers Regions: North America Latin America Europe East Asia South Asia Oceania MEA Get Full Access of this Report through our Secure Payment Gateway Key Questions Covered in the Cancer Biomarkers Market Report What will be the demand outlook for the cancer biomarkers market during the forecast period? Which are the challenges faced in the cancer biomarkers market? Which region will lead the growth in the global cancer biomarkers market during 2022-2032? What is the projected market valuation of the cancer biomarkers market in 2032? Which are the factors driving the cancer biomarkers during 2022-2032? Which test type will generate maximum revenue in the global cancer biomarkers market? Explore Fact.MR's Coverage on the Healthcare Domain Biomarker Detection Systems Market: With increasing prevalence of chronic disorders, the demand for biomarker detection systems is expected to surge. These systems measure the presence and severity of particular disease. As incidence of cardiovascular diseases, cancer, and neurological disorders rise, hospitals and diagnostic centers are improving the adoption of these systems. Biomarkers Market: As per the study, the biomarkers market is expected to witness impressive growth over the next decade. Demand in the market is predicted to increase by 4.1x, reaching nearly US$ 278 Billion by the end of 2032. Country-wise, Japan is expected to be the fastest growing market, registering 17.2% CAGR between 2022 and 2032. Tuberculosis Biomarkers Market: Growing awareness regarding the health check-ups and medication of tuberculosis in developing nations will drive the demand for tuberculosis biomarkers. Further, rising prevalence of multi-drug resistant tuberculosis and growing footfall of patients is accelerating the need for tuberculosis biomarkers. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D) E: [email protected] Follow Us: LinkedIn | Twitter | YouTube Logo: SOURCE Fact.MR

mHealth Apps Sales to Grow 3.8X by 2032 as Demand for Fitness Apps Surges by 13.7% In its latest report, Fact.MR presents an elaborate analysis of various factors influencing the global mHealth apps market, including drivers, opportunities, restraints, and trends. It further delves deeper into major observations concerning prominent expansion parameters prevailing across key segments, including product type and regions. ROCKVILLE, Md., Nov. 16, 2022 /PRNewswire/ -- Revenues in the global mHealth apps market are forecast to grow at 14.3% CAGR between 2022 and 2032. The market generated revenues worth US$ 36.7 Billion in 2021 and registered growth at 11.9% CAGR between 2017 and 2021. Demand in the market is expected to rise as prevalence of chronic disorders such as diabetes, cancer, and other surges. As these diseases require constant monitoring of the patients, the need for mobile applications, especially for people in home-care services is expected to surge. Further, penetration of smartphone across the globe has burgeoned. Nowadays, consumers are relying extensively on mobile applications to track their fitness. Hence, key companies are deploying mHealth apps that are compatible with smartphones and now with smartwatches. Use of fitness apps to track blood pressure, oxygen, and other parameters is increasing, especially among millennials. Hence, key players are extensively investing in research & development activities to capitalize on the growing demand. For instance, in 2020, the American Telemedicine Association partnered with a leading U.K. based digital health evaluator to launch payers, providers, and resources looking for guidance on quality-based mHealth apps across Europe, Middle East, and Australia. As per the study, demand for mHealth apps is predicted to burgeon by 3.8X over the forecast period (2022-2032) and reach a valuation of nearly US$ 155.9 Bn by the end of 2032. Another factor propelling the growth is rising awareness and consciousness regarding the fitness to reduce the risk of lifestyle disorders. Download A Free Sample Copy of this Report! On the back of this, the demand for diet & nutrition related apps is expected to grow at 13.7% CAGR over the assessment period. This is expected to create lucrative growth prospects for the key players in the market, pushing the demand. Key Takeaways: The U.S. is expected to account for more than 1/3rd of total revenues in the global mHealth apps market. China is expected to witness impressive growth at 19% CAGR in the global mHealth apps market. Sales of mHealth apps in Canada are projected to increase at 18.1% CAGR over the upcoming decade. Germany is expected to spearhead the growth in Europe mHealth apps market, with demand increasing at 16.1% CAGR between 2022 and 2032. In 2021, the medical apps segment accounted for nearly 97% of revenue in the global mHealth apps market. The fitness apps category is expected to register 13.4% CAGR during the assessment period. Growth Drivers: Prevalence of chronic disorders that required frequent or constant monitoring is predicted to improve the adoption of mHealth apps. Increasing focus on developing cost-effective healthcare delivery apps and patient-centric delivery care will drive the demand. Restraints: Increased risk of cyber- and data-theft through mHealth apps is expected to be the key factor limiting the growth in the market. Get Customization on this Report for Specific Research Solutions Competitive Landscape: With growing reliance on mobile applications for healthcare, the presence of mHealth apps providers is burgeoning at a rapid pace. This has led to increased competition and deployment of technologically advanced mHealth apps. Leading players in the market are also relying on mergers and strategic collaborations to expand their product portfolio and maintain their dominant position in the industry. For instance, In February 2021, Approov, leading creator of advanced API threat protection for mobile applications, announced a webinar that presents new data from research into API-focused mobile attacks and sponsorship for the research. In 2020, Google announced the launch of an mHealth app for healthcare studies, allowing researchers and providers to collect data from participants using Android phones. Key Companies Profiled by Fact.MR AstraZeneca PLC Abbott laboratories Bristol-Myers Squibb Company Pfizer Inc, Allscripts AT&T Apple Inc Sanofi, Johnson and Johnson Orange Google Inc Samsung Electric Co. ltd, Others More Valuable Insights on mHealth apps Market In the latest study, Fact.MR reveals key factors expected to boost the growth in global mHealth apps market during the forecast period (2022-2032). The survey also provides an in-depth analysis of opportunities and drivers projected to propel sales of mHealth apps through detailed segmentation as follows: Product: Medical Apps Women's Health Apps Personal Health Record Apps Medication Management Apps Diagnostic Apps Remote Monitoring Apps Disease Management Apps Other Medical Apps Fitness Apps Diet & Nutrition Exercise & Fitness Lifestyle & Stress Regions: North America Latin America Europe East Asia South Asia Oceania MEA Explore Our Safe & Secure Payment Options for Quick Buy! Key Questions Covered in the mHealth Apps Market Report What will be the demand outlook for the mHealth apps market during the forecast period? Which are the challenges faced in the mHealth apps market? Which region will lead the growth in the global mHealth apps market during 2022-2032? What is the projected market valuation of the mHealth apps market in 2032? Which are the factors driving the mHealth apps during 2022-2032? Which category will generate maximum revenue in the global mHealth apps market? Explore Fact.MR's Coverage on the Healthcare Domain Mental Health Apps Market: The global mental health apps market is expected to increase from US$ 6.2 Billion in 2022 to US$ 30 Billion in 2032. Growing awareness regarding the mental well-being and depression & anxiety is anticipated to boost the market. Sales in the market are projected to soar at 17% CAGR between 2022 and 2032. mHealth Market: The overall sales in the mHealth market are projected to surge at 12% CAGR during the forecast period. According to the study, the demand in the market is expected to surge by 3x, surpassing the valuation of US$ 177.03 Billion by the end of 2032. North America is expected to account for nearly 2/5th of revenue in the market. Peritoneal Dialysis Solutions Market: The peritoneal dialysis solutions market is expected to witness steady growth over the forecast period on the back of rising incidence of kidney failure across the globe. As per the study, with increasing advancements in healthcare industry and advent of automation, the automated peritoneal dialysis (APD) segment is expected to witness fastest growth. Personal Assistance Apps Market: Global sales of personal assistance applications are projected to increase at a CAGR of 18.3% during 2021 – 2031. Advancing adoption rate of client management software stands as the core driver for the market. About Fact.MR Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range – from automotive & industry 4.0 to healthcare, technology, chemical and materials, to even the most niche categories. We are committed to deliver insights that help businesses gain deeper understanding of their target markets. We understand that making sense of the vast labyrinth of data can be overwhelming for businesses. That's why focus on offering insights that can actually make a difference to bottom-lines. Specialties: Competition Tracking, Customized Research, Syndicated Research, Investment Research, Social Media Research, Business Intelligence, Industry Analysis, Thought Leadership. Contact: Mahendra Singh US Sales Office 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel: +1 (628) 251-1583, +353-1-4434-232 (D) E: [email protected] Follow Us: LinkedIn | Twitter | YouTube Logo: SOURCE Fact.MR